Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Status: Recruiting
Phase:
Diagnosis: Prostate Cancer
NCT ID: NCT01547299 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-089

 

The purpose of this study is to determine if MDV3100 is an effective therapy in treating localized prostate cancer prior to prostatectomy.

 

Conducting Institutions:
Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center, Dana-Farber Cancer Institute

Overall PI:
Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Glenn Bubley, MD, Beth Israel Deaconess Medical Center

Contacts:
Dana-Farber Cancer Institute: Judith Prisby, 617-632-5068, jprisby@partners.org
Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060

Eligibility Criteria

Inclusion Criteria: - Willing to provide informed consent - 18 years of age or older - Histologically confirmed adenocarcinoma of the prostate - Must be a candidate for radical prostatectomy and considered surgically resectable Exclusion Criteria: - Stage T4 prostate cancer by clinical or radiologic evaluation - Treatment with an investigational agent within 4 weeks prior to randomization - Received therapy for for other neoplastic disorders within 5 years - Hypogonadism or severe androgen deficiency
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms